

ACCELERATED COMMUNICATION

Dopamine D₂ Receptor Binding Subunits of $M_r \approx 140,000$ and 94,000 in Brain: Deglycosylation Yields a Common Unit of $M_r \approx 44,000$

KEITH R. JARVIE,¹ HYMAN B. NIZNIK,² and PHILIP SEEMAN

Departments of Pharmacology (K.R.J., P.S.) and Medicine (H.B.N.), University of Toronto, Toronto, Ontario, M5S 1A8 Canada

Received March 29, 1988; Accepted May 16, 1988

SUMMARY

The ligand-binding subunit of the porcine striatal dopamine D₂ receptor was identified by photoaffinity labeling with [¹²⁵I]N-azidophenethylspiperone ([¹²⁵I]NAPS). Upon photolysis, [¹²⁵I]NAPS covalently incorporated into a broad band of apparent $M_r \approx 140,000$ with an appropriate pharmacological profile for D₂ receptors as assessed by autoradiography after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Smaller subunits of apparent $M_r \approx 94,000$ and 34,000 were specifically labeled by [¹²⁵I]NAPS with an appropriate D₂ receptor profile and were similar to the major ligand-binding subunits of photoaffinity-labeled canine striatal D₂ receptors. Photoaffinity labeling in the absence or presence of multiple protease inhibitors did not alter the migration pattern of the $M_r \approx 140,000/94,000$ subunits upon denaturing electrophoresis in either the absence or presence of thiol-reducing/alkylating reagents. In order to investigate the possible basis for the existence of these high molecular weight forms of the D₂ receptor, we assessed the carbohydrate nature of photolabeled D₂ ligand-binding subunits by the use of lectin affinity chromatography and specific exo- and endoglycosidase treatments. Both photoaffinity-labeled D₂ receptor proteins from porcine striatum ($M_r \approx 140,000$ and 94,000) were glycoproteins as indexed by their absorption and specific elution from wheat

germ agglutinin lectin resins. The exoglycosidase neuraminidase altered the electrophoretic mobility of both the $M_r \approx 140,000$ and 94,000 labeled subunits to a single band of apparent $M_r \approx 51,000$. Prior removal of sialic acid residues did not alter the reversible binding characteristics of [³H]spiperone to D₂ receptors. Complete removal of receptor-associated N-linked carbohydrate by the endoglycosidase glycopeptidase F (peptide-N⁴[N-acetyl-β-glucosaminyl]asparagine amidase) produced a further increase in the mobility of the $M_r \approx 51,000$ subunit to apparent $M_r \approx 44,000$. The porcine $M_r \approx 34,000$ photolabeled peptide is an N-linked glycoprotein as assessed by lectin affinity chromatography and susceptibility to digestion by glycopeptidase F to a peptide of apparent $M_r \approx 23,000$. These data suggest that the high molecular weight form of apparent $M_r \approx 140,000$ of the D₂ binding subunit observed in porcine striatal membranes results from glycosylation processing different from that observed in canine brain and that upon complete N-linked deglycosylation both porcine and canine striatal D₂ receptors share at least two common binding subunits of apparent $M_r \approx 44,000$ and 23,000. The exact molecular relation between these two subunits, as well as their role in the maintenance and expression of neuronal D₂ receptor-mediated events, is still unclear.

The recent synthesis and availability of specific radiolabeled photoaffinity probes for the D₂ dopamine receptor has allowed the identification of the ligand-binding subunit of this membrane protein (reviewed in Ref. 1). Photoaffinity labeling with [¹²⁵I]NAPS (2-4), or [³H]azidomethylspiperone (5) followed by SDS-PAGE and autoradiography reveals a polypeptide of $M_r \approx 94,000$ as the major ligand binding subunit of D₂ dopamine receptors. Photoincorporation of these probes into the $M_r \approx$

94,000 subunit is antagonized in a stereoselective manner by dopaminergic agents with a pharmacological profile indicative of the D₂ receptor. In all species studied to date, including rat, hamster, dog, cow, guinea pig, and rabbit, [¹²⁵I]NAPS identifies a protein of apparent $M_r \approx 94,000$ as the ligand binding subunit of neuronal (striatal) D₂ receptors. The $M_r \approx 94,000$ [¹²⁵I]NAPS-labeled protein appears, at least in canine brain, to be heavily glycosylated because removal of N-linked carbohydrates by the endoglycosidase PNGase-F drastically alters the electrophoretic mobility of the $M_r \approx 94,000$ protein to apparent $M_r \approx 44,000$ (4).

Of the other tissues containing D₂ dopamine receptors, only

These studies were supported by the Medical Research Council of Canada, the Ontario Mental Health Foundation, and the Canadian Friends of Schizophrenics.

¹ Recipient of an Ontario Mental Health Foundation Studentship.

² Fellow of the Medical Research Council of Canada.

ABBREVIATIONS: [¹²⁵I]NAPS, [¹²⁵I]N-azidophenethylspiperone; GlcNAc, N-acetylglucosamine; PNGase-F, glycopeptide-N-glycosidase; PMSF, phenylmethylsulfonyl fluoride; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; WGA, wheat germ agglutinin.

in the neurointermediate lobe of rat pituitary has [125 I]NAPS been shown to label a protein of higher molecular weight ($M_r \approx 120,000$) (3). In this report we document that [125 I]NAPS labels a high molecular weight form ($M_r \approx 140,000$) of D_2 receptors from porcine striatal membranes. Moreover, we demonstrate with the use of specific exo- and endoglycosidases that the high molecular weight form of the receptor is due to carbohydrate moieties associated with the ligand binding subunit of the D_2 receptor and that upon complete deglycosylation the M_r of [125 I]NAPS-labeled receptors is the same in different species.

Experimental Procedures

Materials. [125 I]NAPS (2200 Ci/mmol) was purchased from New England Nuclear (Boston, MA) and [3 H]spiperone (85 Ci/mmol) was from Amersham (Arlington Heights, IL). Neuraminidase (purified Type X from *Clostridium perfringens*), Nonidet P-40, PMSF, benzamidine, leupeptin, soybean trypsin inhibitor, GlcNAc, and prestained electrophoresis molecular weight standards were obtained from Sigma Chemical Co. (St. Louis, MO). Glycopeptidase F (peptide- N^4 [N -acetyl- β -glucosaminyl]asparagine amidase) from *Flavobacterium meningosepticum* was from Boehringer Mannheim (Indianapolis, IN). O -Glycanase (endo- α - N -acetylgalactosaminidase) from *Diplococcus pneumoniae* was from Genzyme (Inter Medico, Toronto, Canada). Digitonin was purchased from Wako Chemical Co. (Dallas, TX) and WGA-Sepharose was obtained from Pharmacia Fine Chemicals (Piscataway, NJ). Porcine and canine brains were obtained from Pel-Freez Biologicals (Rogers, AR). Electrophoresis reagents were from Bio-Rad (Richmond, CA). X-ray film (XAR-5) and developing solutions (D-19) were from Eastman Kodak (Rochester, NY). Dopaminergic agents were either purchased from Research Biochemicals (Natick, MA) or were generously donated by various firms as previously described (4, 5).

Membrane preparations. Striata dissected from partially thawed porcine or canine brains were prepared as previously described (4). Briefly, tissues were Teflon-glass homogenized (using 10 up and down strokes of the motor-driven rotating piston) in 20 volumes of ice-cold 25 mM Tris-HCl buffer containing 250 mM sucrose and the following protease inhibitors: 20 mM EDTA, 15 μ g/ml benzamidine, 5 μ g/ml leupeptin, 5 μ g/ml soybean trypsin inhibitor, and 1 mM PMSF (pH 7.4 at 4°). Homogenates were centrifuged at $600 \times g$ for 10 min and the supernatant was collected and recentrifuged at $48,000 \times g$ for 20 min. The resulting pellet was resuspended in 25 mM Tris-HCl buffer containing 100 mM NaCl and protease inhibitors to yield a final protein concentration of ~ 2 –3 mg/ml. For some experiments, membranes were prepared in 25 mM Tris-HCl buffer alone (pH 7.4 at 4°).

Photoaffinity labeling. Membranes (1 ml) were routinely incubated (in the dark) with 50 pM [125 I]NAPS at a D_2 concentration of ~ 50 pM in a total volume of 10 ml for 90 min at 22° in the presence or absence of dopaminergic agents as indicated. After incubation, samples were centrifuged at $48,000 \times g$ for 10 min. Membrane pellets were resuspended in 10 ml of 25 mM Tris-HCl buffer containing 100 mM NaCl, protease inhibitors, and 0.5% bovine serum albumin and recentrifuged. Membranes were resuspended in 1 ml of buffer (without bovine serum albumin) and irradiated for 35 sec as previously described (5). [125 I]NAPS-labeled membranes were sedimented at $48,000 \times g$ for 10 min and used as described below.

D_2 receptor solubilization. Photoaffinity-labeled membranes were solubilized (~ 10 mg/ml) in buffer containing protease inhibitors and 1% digitonin at 4° for 30 min with constant stirring. Samples were centrifuged at $48,000 \times g$ for 1 hr and the supernatant was passed through a 220-nm Millex filter.

WGA-Sepharose chromatography. Digitonin-solubilized labeled receptors (1.8 ml) were applied to a 2-ml open column of WGA-Sepharose, preequilibrated with 50 mM Tris buffer (pH 7.4) containing 100 mM NaCl, protease inhibitors, and 0.1% digitonin at 4°, as previously described (4). Columns were washed with 20 ml of the same

buffer and absorbed receptors were specifically eluted with buffer (as above) containing 300 mM GlcNAc. Solubilized, nonabsorbed, and eluted fractions were lyophilized and subjected to SDS-PAGE, as described below.

Exoglycosidase treatments. For neuraminidase treatment, [125 I]NAPS-labeled membranes were washed twice in 30 ml of 100 mM sodium acetate buffer, pH 5.0, at 22°. Membranes were resuspended in the same buffer at 0.5–1.0 mg/ml, to which neuraminidase was added at a concentration of 2 units/ml. Aliquots were incubated for up to 1 hr at 37°. After incubation, membranes were washed and solubilized in SDS buffer, as described below.

Endoglycosidase treatments. [125 I]NAPS-photolabeled and neuraminidase-treated receptors (as described above) were washed twice in 30 ml of 200 mM sodium phosphate buffer containing 2.5 mM EDTA, pH 8.0, at 22°. Pellets were resuspended in a minimal volume (~ 300 μ l) of the same buffer to which was added 0.5% SDS and 100 mM β -mercaptoethanol and incubated for 1 hr at 22°. Aliquots (30 μ l; corresponding to 0.5–1.0 mg) were incubated with Nonidet P-40 (1.25% final concentration) and PNGase F (at a concentration of 50 units/ml) for 18–24 hr at 37° in a total volume of 60 μ l as previously described (4). After incubation, samples were sedimented at $12,000 \times g$ for 10 min and membranes were solubilized in SDS-PAGE sample buffer, as described below.

[3 H]Spiperone binding assay. Membranes were prepared for neuraminidase treatment (as described above) and washed twice in 100 mM sodium acetate buffer, pH 5.0. Membranes were treated with 2 units/ml of neuraminidase for 15 min at 37°. After treatment, membranes were washed twice in 30 ml of 50 mM Tris-HCl buffer containing 1 mM EDTA, 120 mM NaCl, 1.5 mM CaCl_2 , and 4 mM MgCl_2 and resuspended in the same buffer at a concentration of ~ 0.8 mg/ml. Aliquots (0.5 ml) of control or neuraminidase-treated receptors were incubated with increasing concentrations of [3 H]spiperone (0.1–2.0 nM) for 90 min at 22° in a total volume of 1.5 ml and assayed for D_2 receptor activity by rapid filtration as previously described (4, 5). Nonspecific binding was defined in the presence of 1 μ M (+)-butaclamol. Computer-assisted analyses (LIGAND) of all ligand binding data were as previously described (5).

SDS-PAGE and autoradiography. Electrophoresis was performed as previously described (4, 5). Briefly, photoaffinity-labeled membranes were washed once in Tris-HCl buffer and incubated with 50 mM Tris, 10% glycerol, 10% SDS, and 5% β -mercaptoethanol, pH 6.8, for 1–2 hr at 22°. For lyophilized samples containing digitonin, or for PNGase-F-treated membrane, samples were solubilized in the above buffer containing 20% SDS. Aliquots (100–300 μ g) were loaded on slab gels containing either a 10% or 12% acrylamide separating gel and a 6% stacking gel and electrophoresed overnight. In an attempt to gain greater resolving power in the molecular weight range of interest, a longer separating gel (16–17 cm) was used in most experiments. After electrophoresis, gels were dried and exposed to Kodak film with one intensifying screen at -70° for various amounts of time. To document quantitative incorporation of [125 I]NAPS into D_2 receptor subunits, gel regions of interest were cut out and counted in a Packard gamma counter at $\sim 80\%$ efficiency. Subsequent autoradiography of the cut gels confirmed that the appropriate section was taken. Molecular weights were determined graphically by plotting the log molecular weight of known protein standards versus the R_f (relative migration) of these proteins. The apparent M_r of photolabeled receptors was estimated by determining the R_f (from the center of the band) and interpolating this value on the standard curve. The values given are the means of several experiments.

Results and Discussion

Photoaffinity labeling and pharmacological specificity of [125 I]NAPS photoincorporation in porcine striatal membranes. The ligand binding subunit of striatal D_2 dopamine receptors has been shown to reside on an apparent $M_r \approx$

94,000 protein in numerous species by photoaffinity labeling with [¹²⁵I]NAPS (see Introduction). Fig. 1A depicts the results obtained when porcine striatal membranes were incubated with [¹²⁵I]NAPS and photolyzed and samples were subjected to SDS-PAGE and autoradiography. A broad band was labeled at apparent $M_r \approx 140,000$. The specificity of photoaffinity labeling was shown by virtue of the fact that covalent photoincorporation of [¹²⁵I]NAPS into the $M_r \approx 140,000$ subunit was blocked by 100 nM (+)-butaclamol. Moreover, smaller specifically labeled subunits of apparent $M_r \approx 94,000$ and 34,000 were also seen. The stoichiometry of [¹²⁵I]NAPS photoincorporation into these three subunits was $\sim 4:2:1$. In addition, a nonspecifically labeled band of apparent $M_r \approx 53,000$ was sometimes seen.

The pharmacological specificity of [¹²⁵I]NAPS photoincorporation was assessed further by examining the ability of various dopaminergic agents to block covalent labeling of these subunits. As seen in Fig. 1A, the photolysis-dependent covalent labeling of the subunits at $M_r \approx 140,000$, 94,000, and 34,000 by [¹²⁵I]NAPS was stereoselectively blocked by (+)- and not (–)-butaclamol and by a selective D₂ receptor antagonist (eticlopride) and an agonist (*N*-propylnorapomorphine). In contrast, coincubation of [¹²⁵I]NAPS with a selective D₁ receptor antagonist, SCH-23390, the serotonergic S₂ receptor antagonist methysergide, or the adrenergic agonist noradrenaline did not prevent the covalent incorporation of [¹²⁵I]NAPS into these subunits. Taken together, the data strongly suggest that the apparent $M_r \approx 140,000$, 94,000, and 34,000 proteins are the ligand-binding subunits of the porcine striatal D₂ receptor.

For comparative purposes, Fig. 1B depicts the results ob-

tained when [¹²⁵I]NAPS was incubated with striatal membranes from porcine and canine brain, photolyzed, and subjected to SDS-PAGE and autoradiography. In canine striatal membranes, a broad band centered at $M_r \approx 94,000$ was specifically labeled, as defined by 1 μ M (+)-butaclamol. In addition, another specifically labeled subunit at apparent $M_r \approx 34,000$ was also seen, consistent with previous observations (3, 4). Because both photolabeled porcine and canine striatal membrane were run on the same polyacrylamide gel and subjected to the same experimental procedures, the data suggest that both tissues share the apparent $M_r \approx 94,000$ and 34,000 protein as common ligand-binding subunits but the porcine striatal membrane D₂ receptor contains, in addition, a high molecular weight subunit of apparent $M_r \approx 140,000$. (It should be noted that, due to the differences in D₂ receptor density between porcine and striatal tissues and stoichiometry of photolabeling, the autoradiograph depicting photolabeled porcine D₂ receptors is slightly underexposed, resulting in the apparent loss of specific labeling of the $M_r \approx 34,000$ subunit.) The purpose of the present investigation was, therefore, to investigate the possible molecular basis for the high molecular weight form of the porcine striatal D₂ receptor.

Effects of protease inhibitors. Numerous studies have shown that failure to prevent endogenous protease activity during photoaffinity labeling may result in the generation of lower molecular weight protein fragments displaying the same pharmacological profile as the native receptor (5–8). In order to assess whether both the $M_r \approx 94,000$ and 34,000 subunits were proteolytically derived receptor fragments from the ap-




Fig. 1. Photoaffinity labeling and pharmacological specificity of [¹²⁵I]NAPS photoincorporation into porcine striatal membranes. Membranes were prepared and photoaffinity-labeled with [¹²⁵I]NAPS alone (control) or in the presence of indicated concentrations of competing ligands, as described under Experimental Procedures. Samples were then solubilized and electrophoresed on a 12% acrylamide gel. The M_r of known pre-stained standards are shown $\times 1000$. The results shown are representative of four similar experiments. BTC, butaclamol; ETIC, eticlopride; SCH, SCH-23390 [(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine]; NPA, *N*-propylnorapomorphine; and NA, noradrenaline.

parent $M_r \approx 140,000$ polypeptide, porcine striatal membranes were prepared and photoaffinity labeled in the absence or presence of multiple protease inhibitors. As illustrated in Fig. 2, preparing and photoaffinity labeling porcine striatal membranes in Tris buffer alone did not significantly affect the pattern of [125 I]NAPS incorporation into the subunits of apparent $M_r \approx 140,000$, 94,000 and 34,000, as compared with samples prepared and photolyzed in the presence of multiple protease inhibitors. In the absence of protease inhibitors, a $M_r \approx 52,000$ peptide appeared to be partially displaceable. This band appeared to correspond to the nonspecifically labeled peptide of $M_r \approx 52,000$ observed in canine striatal membranes (Fig. 2). Thus, the inclusion of multiple class-specific protease inhibitors, which have been shown to be useful in preventing receptor degradation in other systems (6–8) and even for photoaffinity-labeled D_2 receptors of rat striatum (3), did not prevent the specific labeling of “lower” molecular weight subunits of apparent $M_r \approx 94,000$ and 34,000 of porcine striata or the $M_r \approx 34,000$ subunit of canine striata, consistent with previous observations (3, 4). These data suggest that either an inappropriate protease inhibitor cocktail was chosen or that the $M_r \approx 94,000$ and 34,000 labeled subunits are not simply proteolytic degradation products of the $M_r \approx 140,000$ protein.

Previous work on both the insulin (9) and β -adrenergic receptors (10) have shown that the M_r of receptors on SDS-PAGE can vary considerably, depending on the reduction-oxidation state of the protein. In order to investigate the possible subunit structure of the apparent $M_r \approx 140,000$ and 94,000 photolabeled subunits, the ability of dithiothreitol (or

β -mercaptoethanol) and *N*-ethylmaleimide to alter the migration pattern of photolabeled receptors was investigated. *N*-Ethylmaleimide (at 10 mM), dithiothreitol (10 mM) or β -mercaptoethanol (10%) added during receptor solubilization in SDS sample buffer did not alter the migration patterns of porcine striatal photoaffinity-labeled bands of apparent M_r of 140,000 and 94,000 (data not shown), as compared with samples prepared in SDS buffer alone. These data indicate that neither the $M_r \approx 140,000$ nor $M_r \approx 94,000$ subunits contain intramolecular disulfide bridges.

Glycoprotein nature of photolabeled D_2 dopamine receptor from porcine brain. [125 I]NAPS photoaffinity-labeled proteins of $M_r \approx 94,000$ and 34,000, representing the ligand-binding subunit of canine striatal D_2 dopamine receptors, have been shown to bind to and be specifically eluted from WGA-Sepharose columns with GlcNAc (4). In order to assess whether photoaffinity-labeled porcine striatal D_2 binding subunits of apparent $M_r \approx 140,000$, 94,000, and 34,000 are glycoproteins, [125 I]NAPS-labeled membranes were solubilized and applied to WGA-Sepharose columns. As depicted in Fig. 3, all three photolabeled subunits of apparent $M_r \approx 140,000$, 94,000, and 34,000 were extracted from porcine striatal membranes by the detergent digitonin. Moreover, under the conditions used, virtually all of the labeled receptor present bound to the resin, as




Fig. 2. Effect of protease inhibitors on the photoaffinity labeling pattern of [125 I]NAPS into D_2 receptors of porcine and canine striatal membranes. Membranes were prepared, photolyzed in the complete absence (Tris buffer alone) or presence of protease inhibitors, and subjected to SDS-PAGE, as described in Experimental Procedures, using a 12% acrylamide gel. The results shown are typical of three similar experiments. Included in the gel are lanes demonstrating nonspecific labeling, as defined by 100 nM (+)-butaclamol, (BTC). M_r of molecular weight standards are shown $\times 1000$.




Fig. 3. WGA-Sepharose chromatography of [125 I]NAPS photoaffinity-labeled D_2 receptors. Porcine striatal membranes were photoaffinity labeled with [125 I]NAPS, solubilized in digitonin, and subjected to WGA-Sepharose chromatography as described in Experimental Procedures. Equal amounts of radioactivity of digitonin-solubilized (~ 1.0 mg) and GlcNAc-eluted (200 μ g) samples were lyophilized and processed for SDS-PAGE on a 12% acrylamide gel, as described in Experimental Procedures. The results shown are representative of two other experiments. M_r of known prestained standards are shown $\times 1000$.

indicated by the lack of radioactivity found in the pass-through and column wash fractions. The addition of 300 mM GlcNAc eluted the labeled receptor-binding subunits with >80% recovery. These data clearly suggest that [¹²⁵I]NAPS-labeled subunits of the porcine D₂ receptor are glycoproteins. The exact mode of porcine D₂ receptor interaction with WGA-Sepharose is unknown, although previous data indicate that D₂ receptor sialic acid residues interact only weakly with the resin (4) and so suggest that the primary site of binding to WGA is probably via poly(*N*-acetylactosamine)-type glycans (11).

To further investigate the nature of the high molecular weight form of the D₂ receptor in this tissue, we analyzed the carbohydrate composition of these photolabeled proteins with the use of specific exo- and endo-glycosidases. Fig. 4A depicts the effects of neuraminidase digestion on both photoaffinity-labeled canine and porcine D₂ dopamine receptors. As previously reported (4), neuraminidase at a concentration of 2 units/ml altered the mobility of the apparent *M_r* ≈ 94,000 subunit to apparent *M_r* ≈ 54,000. Similarly, neuraminidase digestion of [¹²⁵I]NAPS-labeled porcine striatal membranes drastically altered the mobility of the *M_r* ≈ 140,000 and 94,000 subunits to a distinct band at apparent *M_r* ≈ 52,000. Concentration-

effect experiments with neuraminidase revealed that this was the maximal effect seen (data not shown). Inasmuch as neuraminidase specifically cleaves terminal sialic residues, both the [¹²⁵I]NAPS-labeled subunits of *M_r* ≈ 140,000 and 94,000 contain terminal sialic acid. The *M_r* ≈ 34,000 subunit of porcine brain, although not clearly visible in this underexposed autoradiogram, did display a marginal sensitivity to neuraminidase digestion (change of *M_r* ≈ 1000). This is consistent with similar observations made in canine brain (4). However, it should be noted that the *M_r* of these lower molecular weight peptides cannot be accurately determined on these acrylamide gels.

The effect of neuraminidase digestion on the electrophoretic mobility of photolabeled D₂ receptors of canine brain resulted in a diffuse band at apparent *M_r* ≈ 54,000 (Fig. 4A). By increasing the concentration of acrylamide (from 10 to 12%) and the length of the separating gel (from 12 to 16 cm), this band could be resolved into a doublet of apparent *M_r* ≈ 54,000 and 51,000. In contrast, neuraminidase-treated photolabeled striatal membranes from porcine brain migrate as a single band of apparent *M_r* ≈ 51,000 under these conditions (Fig. 4B). Mixing solubilized porcine and canine photolabeled receptors before SDS-PAGE and autoradiography confirmed the existence of post-neuraminidase heterogeneity in canine striatal binding subunits. These data suggest that both porcine and canine labeled striatal D₂ binding subunits share at least one common subunit of *M_r* ≈ 51,000 after neuraminidase treatment. The exact molecular nature of the apparent *M_r* ≈ 54,000 subunit observed in canine striatal membrane is unknown but does not appear to be due to the presence of high mannose-type chains, because sequential neuraminidase and α-mannosidase treatment (12 units/ml) did not alter the migration pattern of the *M_r* ≈ 54,000 subunit (data not shown). Possibly, the *M_r* ≈ 54,000 subunit represents an undifferentiated D₂ receptor fragment whereas the *M_r* ≈ 51,000 subunit is a fully processed form of the receptor. Moreover, it is still unclear whether the neuraminidase-induced change in the electrophoretic mobility of the photolabeled *M_r* ≈ 140,000 and 94,000 binding subunits represents the quantitative cleavage of large amounts of receptor-associated sialic acids or simply relieves the interference caused by negatively charged residues on protein migration in SDS-PAGE.

As listed in Table I, porcine striatal D₂ receptors, after neuraminidase treatment, bound the selective D₂ receptor antagonist [³H]spiperone in a saturable manner. Moreover, the affinity of [³H]spiperone for the neuraminidase-treated receptor was similar to that for control membranes. These data suggest that the receptor-associated sialic acid residues are not necessary for ligand binding to the *M_r* ≈ 51,000 subunit, as has




Fig. 4. Effect of neuraminidase treatment on the D₂ dopamine receptor of the porcine and canine striata. A, [¹²⁵I]NAPS-labeled membranes were prepared for enzyme treatment as described under Experimental Procedures. Neuraminidase was added to the indicated aliquots at 2 units/ml and incubated at 37° for 1 hr. Included in this gel is a lane demonstrating nonspecific labeling (neuraminidase-treated) as defined by (+)-butaclamol. After treatment the samples were prepared and subjected to SDS-PAGE, as described under Experimental Procedures using a 10% acrylamide gel. The relative molecular weights are shown ×1000. This experiment was repeated three times with similar results. B, Porcine or canine striatal [¹²⁵I]-labeled D₂ receptors were treated with neuraminidase as described above and prepared for SDS-PAGE using a 12% acrylamide separating gel of 16–17 cm. An equal mixture of neuraminidase-digested porcine and canine striatal D₂ receptors were also analyzed.

TABLE 1

[³H]Spiperone binding to neuraminidase-treated D₂ receptors

Membranes were prepared and treated with 2 units/ml neuraminidase for 15 min at 37° as described in Experimental Procedures. After incubation, membranes were washed in Tris-HCl buffer and assayed for D₂ receptor activity, as described in Experimental Procedures.

B_{max} and *K_D* values for [³H]spiperone binding were derived from computer-assisted analysis of the data (LIGAND) and are the means ± standard error obtained from three experiments. Simultaneous analysis of control and neuraminidase-treated curves revealed no statistical difference in either the *K_D* or *B_{max}*.

Condition	<i>K_D</i>	<i>B_{max}</i>
	<i>pM</i>	
Control	40 ± 5	18.5 ± 1
Neuraminidase-treated	62 ± 16	18.9 ± 2




Fig. 5. Effect of PNGase-F treatment on the D₂ dopamine receptor binding subunit of porcine striatal membranes. Membranes were labeled with [¹²⁵I]NAPS, treated with 2 units/ml neuraminidase and incubated with sodium phosphate buffer containing 0.5% SDS and 100 mM β-mercaptoethanol for 60 min at 22° as described in Experimental Procedures (lane a). PNGase-F (50 units/ml) was added to the indicated aliquots (lanes b and c) and incubated for 18 hr at 37°. Control samples (lane a; neuraminidase-treated) were subjected to the same experimental procedures but without PNGase-F. Included in this gel is a lane (lane c) demonstrating nonspecific labeling. After treatment, samples were prepared and subjected to SDS-PAGE as described under Experimental Procedures using a 12% acrylamide gel. Molecular weight markers are shown ×1000.

been similarly demonstrated for the canine striatal D₂ receptor (4).

It is still possible, however, that altering the carbohydrate composition of the receptor and, therefore, subunit molecular mass after neuraminidase treatment may influence dopaminergic agonist interaction with D₂ receptors, as has been suggested for the γ-aminobutyric-benzodiazepine receptor complex (12, 13).

The next series of experiments were conducted to gain an approximation of the relative molecular mass of the protein backbone of porcine striatal labeled D₂ receptors. For these experiments neuraminidase-treated labeled membranes were partially denatured and incubated with peptide-N⁴[N-acetyl-β-glucosaminyl]asparagine amidase (N-glycanase; PNGase-F), an enzyme that is capable of removing high mannose, hybrid, and complex-type oligosaccharide chains via hydrolysis of the peptide-N-acetylglucosamine-asparagine bond (14). As illustrated in Fig. 5, control labeled membranes (neuraminidase-treated), which were subjected to the same protocol (but without PNGase-F), migrated on SDS-PAGE with an apparent *M_r* ≈ 51,000 and 34,000 (as described above). The addition of

PNGase-F, at 50 units/ml, further increased the electrophoretic mobility of the *M_r* ≈ 51,000 subunit to apparent *M_r* ≈ 44,000. In addition, the *M_r* ≈ 34,000 subunit was susceptible to PNGase-F digestion, as indicated by its increased mobility to an apparent *M_r* ≈ 23,000. Included in this gel was a lane demonstrating nonspecific labeling. The lack of other new lower molecular weight bands on the gel suggested that little proteolysis was occurring during enzyme treatment. Moreover, the quantitative recovery (>96%) of labeled peptides after treatment suggested that receptor activity was not being degraded to any great extent. The apparent *M_r* ≈ 21,000 subunit seen in Fig. 1A and Fig. 5 is a specifically labeled D₂ receptor binding subunit that does not appear to be glycosylated. The exact molecular nature of this low molecular weight subunit, which is always observed, is unknown.

The significant increase in receptor mobility on SDS-PAGE caused by PNGase-F treatment (>30% of the *M_r* ≈ 34,000 labeled subunit and 15% of the *M_r* ≈ 51,000 subunit) suggests that a large component of receptor-associated carbohydrate chains are N-linked at asparagine residues. In agreement with previous observations on canine striatal membranes (4), the deglycosylated form of porcine D₂ receptors resides in subunits of apparent *M_r* ≈ 44,000 and 23,000, which appear common to both species. Whether there are any additional sites for N-linked glycosylation, as has been suggested for canine striatal D₂ receptors (4), is unknown. Moreover, preliminary evidence suggests that there are no carbohydrate chains O-linked to serine or threonine residues, inasmuch as sequential PNGase-F and O-glycanase treatment (at 1 unit/ml) did not further increase the electrophoretic mobility of the apparent *M_r* ≈ 44,000 or 23,000 subunits. However, given the rather extreme site-specific cleavage requirements for O-glycanase (15), these results must be interpreted with caution.

The exact functional role, if any, of D₂ receptor carbohydrate is unknown. Previous work on β- (16–19) and α₁- (20) adrenergic, acetylcholine (21), and adenosine A₁ (22) receptors revealed little effect of deglycosylation or the inhibition of N-glycosylation in the acquisition of ligand receptor binding characteristics and transmembrane signalling processes. In contrast, receptors for epidermal growth factor (23) and low density lipoprotein (24, 25), and the γ-aminobutyric benzodiazepine receptor complex (12, 13) appear to require receptor carbohydrate for normal ligand binding and function. At least for neuronal D₂ receptors, simple removal of sialic acid is not necessary for saturable and high affinity antagonist binding (this study and Ref. 4). Further work with cultured cell lines may yield more information on the role of N-linked oligosaccharides in receptor function.

In summary, the data presented in the communication indicate that the porcine striatal D₂ receptor is a glycoprotein containing complex-type carbohydrate chains. The relative molecular mass of the N-deglycosylated [¹²⁵I]NAPS-labeled protein backbone residues in two subunits of apparent *M_r* ≈ 44,000 and 23,000, similar if not identical to completely N-deglycosylated D₂ receptors of canine striatal membranes (4). Thus, despite the existence of a high molecular weight form of photo-affinity-labeled neuronal porcine D₂ receptor binding subunit, deglycosylated subunits from both species migrate with similar molecular masses on SDS-PAGE; this suggests that, although different glycosylation pathways or processing occurs in both species, the molecular nature of the D₂ receptor appears to be

similar. It is unclear, however, whether the apparent $M_r \approx 44,000/23,000$ subunits represent the functional D₂ receptor moiety or merely the ligand-binding subunit alone and whether these two proteins are noncovalently or covalently coupled under physiological conditions. Ultimately, studies of the predicted peptide core structure based on cDNA sequences (once obtained) will resolve this issue.

Acknowledgments

We wish to thank Marie Botelho for preparing the manuscript.

References

1. Niznik, H. B. Dopamine receptors: molecular structure and function. *Mol. Cell. Endocrinol.* **54**:1-22 (1987).
2. Amlaiky, N., and M. G. Caron. Photoaffinity labeling of the D₂ dopamine receptor using a novel high affinity radioiodinated probe. *J. Biol. Chem.* **260**:1983-1986 (1985).
3. Amlaiky, N., and M. G. Caron. Identification of the D₂ dopamine receptor binding subunit in several mammalian tissues and species by photoaffinity labeling. *J. Neurochem.* **47**:196-204 (1986).
4. Grigoriadis, D. E., H. B. Niznik, K. R. Jarvie, and P. Seeman. Glycoprotein nature of dopamine D₂ receptors. *FEBS Lett.* **227**:220-224 (1988).
5. Niznik, H. B., D. E. Grigoriadis, and P. Seeman. Photoaffinity labeling of dopamine D₂ receptors by [³H]azido-*N*-methylspiperone. *FEBS Lett.* **209**:71-76 (1986).
6. Benovic, J. L., G. L. Stiles, R. J. Lefkowitz, and M. G. Caron. Photoaffinity labeling of mammalian beta-adrenergic receptors: metal-dependent proteolysis explains apparent heterogeneity. *Biochem. Biophys. Res. Commun.* **110**:504-511 (1983).
7. Leeb-Lundberg, L. M. F., K. E. J. Dickinson, S. L. Heald, J. E. S. Wikberg, P. O. Hagen, J. F. DeBernardis, M. Winn, D. L. Andersen, R. J. Lefkowitz, and M. G. Caron. Photoaffinity labeling of mammalian alpha₁-adrenergic receptors: identification of the ligand binding subunit with a high affinity radioiodinated probe. *J. Biol. Chem.* **259**:2579-2587 (1984).
8. Lindstrom, J., W. Gullick, B. Conti-Tronconi, and M. Ellisman. Proteolytic nicking of the acetylcholine receptor. *Biochemistry.* **19**:4791-4795 (1980).
9. Helmerhorst, E., D. S. Ng, M. L. Moule, and C. C. Yip. High molecular weight forms of the insulin receptor. *Biochemistry.* **25**:2060-2065 (1986).
10. Moxham, C. P., and C. C. Malbon. Fat cell beta₁-adrenergic receptor: structural evidence for existence of disulfide bridges essential for ligand binding. *Biochemistry.* **24**:6072-6077 (1985).
11. Osawa, T., and T. Tsuji. Fractionation and structural assessment of oligosaccharides and glycopeptides by use of immobilized lectins. *Annu. Rev. Biochem.* **56**:21-42 (1987).
12. Kuriyama, K., and J. I. Taguchi. Glycoprotein as a constituent of purified gamma-aminobutyric acid/benzodiazepine receptor: structures and physiological roles of its carbohydrate chain. *J. Neurochem.* **48**:1897-1903 (1987).
13. Sweetnam, P. M., and J. F. Tallman. Regional difference in brain benzodiazepine receptor carbohydrates. *Mol. Pharmacol.* **29**:299-306 (1986).
14. Plummer, T. H., J. H. Elder, S. Alexander, A. W. Phelan, and A. L. Tarentino. Demonstration of the peptide:*N*-glycosidase F activity in endo- β -*N*-acetylglucosaminidase F preparations. *J. Biol. Chem.* **259**:10700-10704 (1984).
15. Umemo, J., V. P. Bhavandan, and E. A. Davidson. Purification and properties of an endo- α -*N*-acetyl-D-galactosaminidase from *Diplococcus pneumoniae*. *J. Biol. Chem.* **252**:8609-8614 (1977).
16. Benovic, J. L., C. Staniszewski, R. A. Cerione, J. Codina, R. J. Lefkowitz, and M. G. Caron. The mammalian beta-adrenergic receptor: structural and functional characterization of the carbohydrate moiety. *J. Recept. Res.* **7**:257-281 (1987).
17. George, S. T., A. E. Ruoho, and C. C. Malbon. *N*-Glycosylation in expression and function of β -adrenergic receptors. *J. Biol. Chem.* **261**:16559-16564 (1986).
18. Severne, Y., R. Jurss, and G. Vauquelin. Deglycosylated mammalian beta₂-adrenergic receptors are still able to undergo functional coupling to N_s. *Biochem. Pharmacol.* **35**:4375-4380 (1986).
19. Stiles, G. L. Deglycosylated mammalian beta₂-adrenergic receptors: effect on radioligand binding and peptide mapping. *Arch. Biochem. Biophys.* **237**:65-71 (1985).
20. Sawutz, D. G., S. M. Lanier, C. D. Warren, and R. M. Graham. Glycosylation of the mammalian α_1 -adrenergic receptor by complex type *N*-linked oligosaccharides. *Mol. Pharmacol.* **32**:565-571 (1987).
21. Smith, M. M., S. Schlesinger, J. Lindstrom, and J. P. Merlie. The effect of inhibiting oligosaccharide trimming by 1-deoxynojirimycin on the nicotinic acetylcholine receptor. *J. Biol. Chem.* **261**:14825-14832 (1986).
22. Klotz, K. N., and M. J. Lohse. The glycoprotein nature of A₁ adenosine receptors. *Biochem. Biophys. Res. Commun.* **140**:406-413 (1986).
23. Sleiker, L. J., and M. D. Lane. Post-translational processing of the epidermal growth factor-receptor: glycosylation-dependent acquisition of ligand-binding capacity. *J. Biol. Chem.* **260**:687-691 (1985).
24. Kingsley, D. M., K. F. Kozarsky, L. Hobbie, and M. Krieger. Reversible defects in *O*-linked glycosylation and LDL receptor expression in a UDP-gal/UDP-galNAc 4-epimerase deficient mutant. *Cell* **44**:749-756 (1986).
25. Hobbie, L., D. M. Kingsley, K. F. Kozarsky, R. W. Jackman, and M. Krieger. Restoration of LDL receptor activity in mutant cells by intracellular junctional communication. *Science (Wash. D. C.)* **235**:69-73 (1987).

Send reprint requests to: H. B. Niznik, Department of Pharmacology, University of Toronto, Medical Sciences Building, Toronto, Ontario M5S 1A8, Canada.